Similar to oncogenic kinase drivers observed in myeloid disorders, JAK2 alterations were identified to be driving ALL lesions, offering renewed hope for precision medicine approaches beyond high intensity combination chemotherapy. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.